Lilly’s $3B European Bet Signals Pharma’s Manufacturing Revolution
Eli Lilly’s massive $3 billion investment in the Netherlands represents more than just another factory. This strategic move signals a fundamental shift in pharmaceutical manufacturing and Europe’s growing importance in the global biotech landscape.